DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,989,376 B2 Watkins Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,989,376 B2 Watkins Et Al USOO6989376B2 (12) United States Patent (10) Patent No.: US 6,989,376 B2 Watkins et al. (45) Date of Patent: Jan. 24, 2006 (54) METHODS FOR INCREASING BLOOD 2003/0114415 A1 6/2003 Wurtman et al. ............. 514/51 CYTIDINE AND/OR URIDINE LEVELS AND TREATING CYTIDNE-DEPENDENT HUMAN FOREIGN PATENT DOCUMENTS DISEASES EP O178267 * 4/1986 EP O178267 A2 * 4/1986 (75) Inventors: Carol Watkins, Cambridge, MA (US); JP 07/215879 A * 8/1995 Richard J. Wurtman, Boston, MA JP T215879 * 8/1995 (US) JP 09/30976 A2 * 2/1997 JP 2001/233776 A2 * 8/2001 (73) Assignee: Massachusetts Institute of 2003. A. : is: Technology, Cambridge, MA (US) WO WO 89/03837 A1 * 5/1989 (*) Notice: Subject to any disclaimer, the term of this W woo. S. A1 *: E. patent is extended or adjusted under 35 WO 974.3899 * 11/1997 U.S.C. 154(b) by 0 days. WO WO 97/43899 A1 * 11/1997 WO WO97/43899 A1 * 11/1997 (21) Appl. No.: 09/363,748 WO WO97/45127 A1 * 12/1997 WO 974.5127 * 12/1997 (22) Filed: Jul. 30, 1999 WO WO 97/45127 A1 * 12/1997 O O WO WO OO/5.0043 A1 * 8/2000 (65) Prior Publication Data WO WOOO/5.0043 A1 * 8/2000 US 2002/0028787 A1 Mar. 7, 2002 OTHER PUBLICATIONS Related U.S. Application Data Page et al., “Developmental Disorder Associated with (60) Provisional application No. 60/095,002, filed on Jul. 31, Increased Cellular Nucleotidase Activity,” Proc. National 1998. Academy of Sciences USA, 94(21), 11601-11606 (Oct. 14, (51) Int. Cl. 1997).* A6 IK3I/70 (2006.01) (Continued) (52) U.S. Cl. .............................. 514/50; 514/49; 514/51 Primary Examiner Thomas C. McKenzie (58) Field of Classification Search ................... 514/49, ASSistant Examiner-L. E. Crane 514/50, 51 (74) Attorney, Agent, or Firm-Pearl Cohen Zedek Latzer See application file for complete Search history. LLP; Mark Cohen (56) References Cited (57) ABSTRACT U.S. PATENT DOCUMENTS Methods of treating certain neurological diseases using exogenous uridine or a uridine Source alone as a precursor 4,960,759 A 10/1990 De Luca et al. .............. 514/50 of endogenous cytidine, particularly in the human brain, are 5,141,943 A 8/1992 Naguib et al. ......... ... 514/270 disclosed. Methods are also disclosed wherein exogenous 3. A 8. E. SO etc. a - - - - - - - - - - 5. uridine or a uridine Source is combined either with drugs 2- Y- OaCOSS C a increasing uridine availability or with compounds that Serve 5. A : 3.19. SAGE - - - - - - - - - - 5. as a Source of choline in phospholipid synthesis. 5.962,459 A * 10/1999 Piazza et al. ............... 514/269 6,472.378 B2 * 10/2002 von Borstel et al. .......... 514/50 8 Claims, 3 Drawing Sheets 0.2000 -0.2000 - 0.1000 - 0.1000 w 11.99 0.00-- ---, -, -----a-0.0000 5.00 0.00 1100 US 6,989,376 B2 Page 2 OTHER PUBLICATIONS Ott et al. (I), “Effects of RNA Precursors on Development and Maintenance of Long-Term Memory,” Psychopharma Coirault et al., “Uridine 5-Triphosphate in Therapy. I. Cure cologia, 28(2), 195-204 (1973); Chemical Abstracts, of Neurogenic Muscular Atrophy.” La Presse Medicale(Fr.), 78(19), p. 77, Abstr. No. 119731q, (May 14, 1973).* 68(29), 1127–1129 (Jun. 11, 1960); Chemical Abstracts, Ott et al. (II), “Influence of 6-AZauridine on Facilitation of 57(7), p. 73, Abstract No. 10485f (Oct. 1, 1962).* Relearning by Precursors of Ribonucleic Acid.” Psychop Merlini et al., “Effects of Large Doses of Pyrimidine harmacologia, 23(3), 272-278 (1972); Chemical Abstracts, Nucleosides Cytidine and Uridine in Elderly Patients with 76(25), p. 103, Abstr. No. 149588z, (Jun. 19, 1972).* Neuropsychological Disturbances Caused by Vascular and A. Lehninger, Biochemistry, Second Edition, Worth Publish Cerebral Metabolic Insufficiency,” Gazzetta Medica Italiana ers, Inc., New York, NY, Jul., 1978, only pp. 735-737 Archivio Scienze Mediche, 145(6), 379–390 (Jun., 1966); Supplied.* Biological Abtracts, 83, Abstract No. 27367 (1987).* Gallai et al. (I), “Effects of Uridine in the Treatment of Gibbons et al., Biochemistry of Cholesterol, Elsevier Bio Diabetic Neuropathy: An Electrophysiological Study,” Acta medical Press, New York, NY, 1982, only pp. 258 and 259 Neurol. Scand., 86(1), 3–7 (1992); Biological Abtracts, 94, Supplied.* Abstract No. 112030 (1992).* Lodish et al., Molecular Cell Biology, W. H. Freeman & Co., Gallai et al. (II), “Multi-Infarct Dementia: Modification of New York, NY, 2000, only pp. 68–78 supplied, see espe the P300 Cognitive Event-Related Potential in Patients cially pp. 75–76.* Treated with the Association of Cytidine and Uridine,” Zaffaroni et al., “Adrenal Conversion of C. Labeled Cho Rivista di Neuropsichiatria e Science Afini, 41(1), 1-9 lesterol and Acetate to Adrenal Cortical Hormones,” Journal (1995); BIOSIS, 1996, Abstract Citation No. 466219; only of the American Chemical Society, 73, 1390–1391 (Mar. Abstract supplied.* 1951).* Drago et al., “Memory Deficits of Aged Male Rats Can Be Kato et al., “Determinants of Sex Hormone Levels in Men Improved by Pyrimidine Nucleosides and N-Acetyl as Useful Indices in Hormone-Related Disorders,” Journal glutamine,” Clinical Neuropharmacology, 13(4), 290–296 of Clinical Epidemiology, 45(12), 1417–1421 (Dec., 1992).* (1990); Biological Abstracts, 90, Abstract No. 91117 (YA) Gibbons et al., Biochemistry of Cholesterol, Elsevier (1990).* Biomedical Press, New York, NY, 1982, only pp. 258 and Manna et al., “Effects of Short-Term Administration of 259 Supplied.* Cytidine, Uridine and L-Glutamine Alone or in Combina (ZA) Lodish et al., Molecular Cell Biology, W. H. Freeman tion on the Cerebral Electrical Activity of Patients with & Co., New York, NY, 2000, only pp. 68-78 supplied, see Chronic Cerebrovascular Disease.” Intl. Journal Clinical especially pp. 75-76.* Pharmacology Research, 8(3), 199–210 (1988); Biological Abstracts, 86, Abstract No. 51989 (1988).* (RB) Zaffaroni et al., “Adrenal Conversion of C14 Labeled Keilbaugh et al., “Anti-Human Immunodeficiency Virus Cholesterol and Acetate to Adrenal Cortical Hormones,” Type 1 Therapy and Peripheral Neuropathy: Prevention of Journal of the American Chemical Society, 73, 1390-1391 2',3'-Dideoxycytidine Toxicity in PC12 Cells, a Neuronal (Mar, 1951).* Model, by Uridine and Pyruvate,” Molecular Pharmacol (SB) Kato et al., “Determinants of Sex Hormone Levels in ogy, 44(4), 702–706 (Oct. 1, 1993); BIOSIS, 1994, Abstract Men as Useful Indices in Hormone-Related Disorders,” Citation No. 413648. Journal of Clinical Epidemiology, 45(12), 1417–1421 (Dec., Popov et al., “Protective Effect of Uridine on D-Galac 1992).* tosamine-Induced Deficiency in Brain Uridine Phosphates.” R. Page et al., “Developmental Disorder Associated with Biomedica Biochimica Acta, 43(12), 1399–1404 (1984); Increased Cellular Nucleotidase Activity,” Proc. National Biological Abstracts, 80, Abstract No. 34525 (1985).* Academy of Sciences USA, 94(21), 11601-11606 (Oct. 14, Ingraham et al., “Nucleoside Diphosphokinase from Salmo 1997).* nella typhimurium,” Chapter 48 in Methods in Enzymology, (S) Coirault et al., “Uridine 5-Triphosphate in Therapy. I. LI(vol. 51), Hoffee et al. (eds.), New York, NY, 1978, Cure of Neurogenic Muscular Atrophy,” La Presse Medi Academic Press, only pp. 371 and 375 Supplied; assorted cale(Fr.), 68(29), 1127–1129 (Jun. 11, 1960); Chemical portions of other chapters were also Supplied including pp. Abstracts, 57(7), p. 73, Abstract No. 10485f (Oct. 1, 1962).* 305, 306, 318, 327, 329 and 330.* (T) Merlini et al., “Effects of Large Doses of Pyrimidine Miyazaki et al., “Effects of Nucleotides on Learning and Nucleosides Cytidine and Uridine in Elderly Patients with Memory in a Morris Water Maze Test in Normal and Basal Neuropsychological Disturbances Caused by Vascular and Forebrain-Lesioned Rats,” Life Sciences, 64(1), 45-52 Cerebral Metabolic Insufficiency,” Gazzetta Medica Italiana (Nov. 27, 1998).* Archivio Scienze Medic. Entingh et al., “Brain Uridine Monophosphate: Reduced (U) Gallai et al. (I), “Effects of Uridine in the Treatment of Incorporation of Uridine During Avoidance Learning.” Diabetic Neuropathy: An Electrophysiological Study,” Acta Brain Research, 70(1), 131-138 (Apr. 12, 1974); only Neurol. Scand., 86(1), 3-7 (1992); Biological Abtracts, 94, abstract Supplied.* Abstract No. 112030 (1992).* Rithrich et al., “Increase of Guanosine Incorporation into (V) Gallai et al. (II), “Multi-Infarct Dementia: Modification RNA of Hippocampal Neurons by Application of Uridine of the P300 Cognitive Event-Related Potential in Patients Monophosphate During a Learning Experiments, Brain Treated with the Association of Cytidine and Uridine,” Research, 69(1), 49-55 (Mar. 29, 1974); only abstract Sup Rivista di Neuropsichiatria e Science Affini, 41(1), 1-9 plied.* (1995); BIOSIS, 1996, Ab.* US 6,989,376 B2 Page 3 (W) Drago et al., “Memory Deficits of Aged Male Rats Can Gallai et al.(I), “Effects of Uridine in the Treatment of Be Improved by Pyrimidine Nucleosides and N-Acetyl Diabetic Neuropathy An Electrophysiological Study,” Acta glutamine,” Clinical Neuropharmacology, 13(4), 290–296 Neurol. Scand., 86(1), 3-7 (1992); Biological Abstracts, 94, (1990); Biological Abstracts, 90, Abstract No. 91117 Abstract No. 112030 (1992); only Abstract supplied.* (1990).* Gallai et al.(II), “Multi-Infarct Dementia: Modification of (X) Manna et al., “Effects of Short-Term Administration of the P300 Cognitive Event-Related Potential in Patients Cytidine, Uridine and L-Glutamine Alone or in Combina Treated with the Association of Cytidine and Uridine,” tion on the Cerebral Electrical Activity of Patients with Rivista di Neuropsichiatria e Science Afini, 41(1), 1-9 Chronic Cerebrovascular Disease.” Intl. Journal Clinical (1995); BIOSIS, 1996, Abstract Citation No. 466219; only Pharmacology Research, 8(3).* Abstract supplied.* (Y)Keilbaugh et al., “Anti-Human Immunodeficiency Virus Drago et al., “Memory Deficits of Aged Male Rats Can Be Type 1 Therapy and Peripheral Neuropathy: Prevention of 2 Improved by Pyrimidine Nucleosides and N-Acetyl 3"Dideoxycytidine Toxicity in PC12 Cells, a Neuronal glutamine,” Clinical Neuropharmacology, 13(4), 290–296 Model, by Uridine and Pyruvate,” Molecular Pharamcology, (1990); Biological Abstracts, 90, Abstract No.
Load more

Recommended publications
  • SYNTHESIS and BIOLOGICAL Actnnry of CONFORMATIONALLY CONSTRAINED WLEOSIDES and NUCLEOTIDES
    SYNTHESIS AND BIOLOGICAL ACTnnrY OF CONFORMATIONALLY CONSTRAINED WLEOSIDES AND NUCLEOTIDES A thesis submitted in conformity with the requirements for the degree of Masters of Science Graduate Department of Chemistry University of Toronto National Library Bibliothèque nationaie B*m ofCanada du Canada Acquisitions and Acquisitions et Bibliographie Setvices services bibliographiques 395 Wellington Street 395. rue Wellington ûttawaON K1AW OctawaON KlAW canada canada The author has granted a non- L'auteur a accorde une licence non exclusive Licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distn'buer ou copies of this thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/fïlm, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fiom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. Spthesis and Biologicai Activity of Conformationaliy Constrained NucIeosides and Nuc1eotides Degree of Master of Science, 1998 by Girolamo Tusa Graduate Department of Chemistry, University of Toronto This thesis outhes the synthesis of a variety of confonnationally constrained nucleosides and nucleotide analogues. The conformationally 'locked" analogues closely resemble specific conformers of natural nucleosides and nucieotides and were used to probe the conformationai specificity of particular physiological processes in PC 12 ce&; nucleoside transport (NT) activity and Pt-purinoceptor response.
    [Show full text]
  • Chronotropic, Dromotropic and Inotropic Effects of Dilazep in the Intact Dog Heart and Isolated Atrial Preparation Shigetoshi CH
    Chronotropic, Dromotropic and Inotropic Effects of Dilazep in the Intact Dog Heart and Isolated Atrial Preparation Shigetoshi CHIBA, M.D., Miyoharu KOBAYASHI, M.D., Masahiro SHIMOTORI,M.D., Yasuyuki FURUKAWA, M.D., and Kimiaki SAEGUSA, M.D. SUMMARY When dilazep was administered intravenously to the anesthe- tized donor dog, mean systemic blood pressure was dose depend- ently decreased. At a dose of 0.1mg/Kg i.v., the mean blood pressure was not changed but a slight decrease in heart rate was usually observed in the donor dog. At the same time, a slight but significant decrease in atrial rate and developed tension of the iso- lated atrium was induced. Within a dose range of 0.3 to 1mg/Kg i.v., dilazep caused a dose related decrease in mean blood pressure, bradycardia in the donor dog, and negative chronotropic, dromo- tropic and inotropic effects in the isolated atrium. At larger doses of 3 and 10mg/Kg i.v., dilazep caused marked hypotension, fre- quently with severe sinus bradycardia or sinus arrest, especially in isolated atria. When dilazep was infused intraarterially at a rate of 0.2-1 ƒÊ g/min into the cannulated sinus node artery of the isolated atrium, negative chrono- and inotropic effects were dose dependently in- duced. With respect to dromotropism, SA conduction time (SACT) was prolonged at infusion rates of 0.2 and 0.4ƒÊg/min. But at 1ƒÊg, dilazep caused an increase or decrease of SACT, indicating a shift of the SA nodal pacemaker. It is concluded that dilazep has direct negative chrono-, dromo- and inotropic properties on the heart at doses which produced no significant hypotension.
    [Show full text]
  • Use of Uridine in Combination with Choline for the Treatment Of
    (19) TZZ ¥ _T (11) EP 2 329 829 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/7072 (2006.01) A61K 31/14 (2006.01) 16.04.2014 Bulletin 2014/16 A61K 31/685 (2006.01) A61P 25/28 (2006.01) (21) Application number: 10075661.8 (22) Date of filing: 30.07.1999 (54) Use of uridine in combination with choline for the treatment of neurological disorders Verwendung von Uridin in Kombination mit Cholin zur Behandlung neurologischer Erkrankungen Utilisation de l’uridine en combinaison avec la choline pour le traitement des maladies neurologiques (84) Designated Contracting States: • CACABELOSR ET AL: "THERAPEUTIC EFFECTS AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU OF CDP-CHOLINE IN ALZHEIMER’S DISEASE MC NL PT SE COGNITION, BRAIN MAPPING, CEREBROVASCULAR HEMODYNAMICS, AND (30) Priority: 31.07.1998 US 95002 P IMMUNE FACTORS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK (43) Date of publication of application: ACADEMY OF SCIENCES, NEW YORK, NY, US, 1 08.06.2011 Bulletin 2011/23 January 1996 (1996-01-01), pages 399-403, XP008065562, ISSN: 0077-8923 (62) Document number(s) of the earlier application(s) in • SPIERS P A ET AL: "CITICOLINE IMPROVES accordance with Art. 76 EPC: VERBAL MEMORY IN AGING", ARCHIVES OF 09173495.4 / 2 145 627 NEUROLOGY, AMERICAN MEDICAL 07116909.8 / 1 870 103 ASSOCIATION, CHICAGO, IL, US, vol. 53, no. 5, 99937631.2 / 1 140 104 1 May 1996 (1996-05-01), pages 441-448, XP008028412, ISSN: 0003-9942 (73) Proprietor: Massachusetts Institute of Technology • WEISS G B: "Metabolism and actions of CDP- Cambridge, Massachusetts 02142-1601 (US) choline as an endogenous compound and administered exogenously as citicoline.", LIFE (72) Inventors: SCIENCES 1995 LNKD- PUBMED:7869846, vol.
    [Show full text]
  • The Effects of Intravenously Infused Vasodilators on the Renal Plasma Flow and Renal Tubules
    THE KURUME MEDICAL JOURNAL 1976 Vol.23, No.3, p.121-127 THE EFFECTS OF INTRAVENOUSLY INFUSED VASODILATORS ON THE RENAL PLASMA FLOW AND RENAL TUBULES YOON-YOUNG KIM Department of Pharmacology, Chung-ang University College of Medicine, Seoul, Korea (Received for publication July 29, 1976, introduced by Dr. M. Shingu) Nitroglycerin increased the renal plasma flow and altered electrolyte excretion. Perhexiline, i. v., caused an increase in sodium, chloride and osmolar clearance without the changes in the renal plasma flow. An eleva- tion of the tubular sodium rejection fraction probably contributed to the increased solute clearance. I soproterenol caused retention of sodium, chloride potassium, and water without changing the renal plasma flow or the glomerular filtration rate. The tubular rejection fraction of sodium was decreased, indicating that isoproterenol was directly increasing the tubular reabsorption. The renal changes induced by isoproterenol were not altered by pretreatment with perhexiline. INTRODUCTION In this study we selected two proto types of coronary vasodilators : nitro- Drugs which dilate the coronary glycerin and perhexiline HCl. The phar- arteries also affect other vascular beds. macological properties of perhexiline Since coronary vasodilators are pre- have been reported before (Cho et al., scribed for long periods of time, this 1970; Matsuo et al., 1970). Briefly, it effect on renal function and vasculature possess similar, as well as dissimilar, is an important consideration. We have pharmacological properties to that of reported previously on the unexpected nitroglycerin. Like nitroglycerin, per- effects of hexobendine on renal function hexiline is a coronary vasodilator and (Cho et al., 1973). Hexobendine is a its anti-anginal efficacy is currently portent coronary vasodilator whose bio-.
    [Show full text]
  • Long-Term Oral Administration of Dipyridamole Improves Both
    913 Hypertens Res Vol.30 (2007) No.10 p.913-919 Original Article Long-Term Oral Administration of Dipyridamole Improves Both Cardiac and Physical Status in Patients with Mild to Moderate Chronic Heart Failure: A Prospective Open-Randomized Study Shoji SANADA1),2), Hiroshi ASANUMA3), Yukihiro KORETSUNE4), Kouki WATANABE5), Shinsuke NANTO6), Nobuhisa AWATA7), Noritake HOKI2), Masatake FUKUNAMI2), Masafumi KITAKAZE3), and Masatsugu HORI1) Adenosine is known as an endogenous cardioprotectant. We previously reported that plasma adenosine lev- els increase in patients with chronic heart failure (CHF), and that a treatment that further elevates plasma adenosine levels may improve the pathophysiology of CHF. Therefore, we performed a prospective, open- randomized clinical trial to determine whether or not exposure to dipyridamole for 1 year improves CHF pathophysiology compared with conventional treatments. The study enrolled 28 patients (mean±SEM: 66±4 years of age) attending specialized CHF outpatient clinics with New York Heart Association (NYHA) class II or III, no major complications, and stable CHF status during the most recent 6 months under fixed medica- tions. They were randomized into three groups with or without dipyridamole (Control: n=9; 75 mg/day: n=9; 300 mg/day: n=10) in addition to their original medications and were followed up for 1 year. The other drugs were not altered. Among the enrolled patients, 100%, 4%, 100%, and 79% received angiotensin-converting enzyme inhibitors, aldosterone analogue, loop diuretics, and β-adrenoceptor blocker, respectively. Fifteen patients suffered from dilated cardiomyopathy, and 7/3/3 patients suffered from ischemic/valvular/hyperten- sive heart diseases, respectively. Mean blood pressure was comparable among the groups.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Mechanisms of Uptake and Resistance to Troxacitabine, a Novel Deoxycytidine Nucleoside Analogue, in Human Leukemic and Solid Tumor Cell Lines
    [CANCER RESEARCH 61, 7217–7224, October 1, 2001] Mechanisms of Uptake and Resistance to Troxacitabine, a Novel Deoxycytidine Nucleoside Analogue, in Human Leukemic and Solid Tumor Cell Lines Henriette Gourdeau,1,2 Marilyn L. Clarke,1 France Ouellet, Delores Mowles, Milada Selner, Annie Richard, Nola Lee, John R. Mackey, James D. Young,3 Jacques Jolivet, Ronald G. Lafrenie`re, and Carol E. Cass4 Shire BioChem Inc., Laval, Que´bec, H7V 4A7 Canada [H. G., F. O., A. R., N. L., J. J., R. G. L.]; Departments of Oncology [M. L. C., J. R. M., C. E. C.] and Physiology [J. D. Y.], University of Alberta, Alberta T6G 1Z2 Canada; and Cross Cancer Institute, Edmonton, Alberta T6G 1Z2 Canada [M. L. C., D. M., M. S., J. R. M., C. E. C.] ABSTRACT oxycytidine analogues such as gemcitabine (2Ј,2Ј-difluorodeoxycyti- dine; dFdC) and cytarabine (1-␤-D-arabinofuranosylcytosine; araC), -Troxacitabine (Troxatyl; BCH-4556; (-)-2؅-deoxy-3؅-oxacytidine), a de which are in the ␤-D configuration, troxacitabine has a nonnatural ␤-L oxycytidine analogue with an unusual dioxolane structure and nonnatural configuration. Troxacitabine, which shares the same intracellular ac- L-configuration, has potent antitumor activity in animal models and is in clinical trials against human malignancies. The current work was under- tivation pathway as gemcitabine and cytarabine, undergoes a series of taken to identify potential biochemical mechanisms of resistance to trox- phosphorylation reactions through a first rate-limiting step catalyzed 5 acitabine and to determine whether there are differences in resistance by dCK (EC 2.7.1.74) to form the active triphosphate nucleotide.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Brian F King and Andrea Townsend- Nicholson University College
    BrianFKingandAndreaTownsend- P2XReceptors Nicholson P2Xreceptors(P2XRs)areligand-gatedion-channels (LGICs)widelydistributedamongstvarioustissue UniversityCollegeLondon,GowerStreet, types,includingautonomic,central,entericand London,WC1E6BT,UK. sensoryneurons,cochlearandretinalcells, endotheliumandepithelium,vascularandvisceral BrianKingisaSeniorLecturerinthe smoothmuscle,heartanddevelopingskeletal DepartmentofPhysiology,andAndrea muscle,bone,haemopoieticcells.TheseLGICsserve Townsend-NicholsonaLecturerinthe tocontroltheexcitabilityoftheirhostcellsthrough DepartmentofBiochemistryandMolecular twoprocesses:i)influxofextracellularsodiumionsto elicitdepolarisation,andii)influxofextracellular Biology.Theyshareacommoninterestin calciumionstoactivateinternalenzymes. purinesignallingatrecombinantandnative P1andP2receptorsandhaveworked P2XRassembly togetheroverthelastsevenyearsonthe Sevenbuildingblocks, orsubunitproteins,are isolationandcharacterisationofnucleotide involvedintheconstructionofP2XRs.Theseseven receptors. buildingblocks–theP2X17toP2Xsubunits–have beenclonedfromhumanandratcDNAlibrariesand, insomecases,alsofrommouse,guinea-pig,chick andzebrafishlibraries.1,2 Fewstructuraldifferences havebeennotedbetweenspeciesorthologuesofthe Introduction sameP2Xsubunit.However,thedegreeofhomology canbeaslittleas27%betweendifferentsubunitsof Extracellularnucleotidesignallingmolecules,suchas thesamespecies.1 Furthermore,theP2Xgenesare ATP,ADP,UTPandUDP,workthroughspecific complexand,duringtranscription,canundergo ionotropic(P2X)ormetabotropic(P2Y)cell-surface
    [Show full text]
  • Effect of Oren-Gedoku-To on Platelet Aggregation
    Acta Medica et Biologica Vol. 39, No.4, 153-159 1991 Effect of Oren-gedoku-to on Platelet Aggregation Ken-ichi WATANABE Yasushi MIYAKITA Takayuki INOMATA Masataka SUZUKI Minoru TAKAHASHI Sen KOYAMA Kaoru SUZUKI Fumiaki MASANI and Akira SHIBATA IDivision of Cardiology, Tsubame Rosai Hospital Sawatari 633, Tsubame City Niigata 959-12 and 2Department of Internal Medicine I, Niigata University School of Medicine Received April 5, 1991 Summary. A traditional Chinese herbal medicine hypertension in 8 patients, and myocardial infarction "Oren-gedoku-to" (~Jlf9irll~) was administered to 21 in 4 patients. The population consisted of 3 males and patients with cerebrovascular disease. In 17 cases (81 %) 18 females aged 45 to 82 (70 ± 8, mean± ISD) years. symptomatic improvement was observed. Abnormally At least six months had elapsed after the first TIA, increased platelet aggregation in three cases returned myocardial infarction, or cerebral infarction. No to normal levels after administration. Oren-gedoku-to platelet aggregation inhibitors nor anti-coagulant may be useful for patients with cerebrovascular disease who present vague complaints. drugs had been administered (particularly, ticlopidine, dipyridamole, trapidil, dilazep, cilostazol, halidor, or warfarin). Other medicines were given continually during the examination period. The prescriptions and INTRODUCTION dosages were maintained as consistently with the original as possible. Essential hypertension, diabetes mellitus and hyper­ A daily dosage of 5.0-7.5 grams of oren-gedoku-to lipidemia are known risk factors for myocardial was orally administered. Before and 14 days after the infarction and cerebral infarction. Increased platelet initial administration, the following examinations aggregation has more recently been recognized as were conducted early in the morning: another risk factor.
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug
    USOO544607OA United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug. 29, 1995 54 COMPOST ONS AND METHODS FOR 4,659,714 4/1987 Watt-Smith ......................... 514/260 TOPCAL ADMNSTRATION OF 4,675,009 6/1987 Hymes .......... ... 604/304 PHARMACEUTICALLY ACTIVE AGENTS 4,695,465 9/1987 Kigasawa .............................. 424/19 4,748,022 5/1988 Busciglio. ... 424/195 75 Inventor: Juan A. Mantelle, Miami, Fla. 4,765,983 8/1988 Takayanagi. ... 424/434 4,789,667 12/1988 Makino ............ ... 514/16 73) Assignee: Nover Pharmaceuticals, Inc., Miami, 4,867,970 9/1989 Newsham et al. ... 424/435 Fla. 4,888,354 12/1989 Chang .............. ... 514/424 4,894,232 1/1990 Reul ............. ... 424/439 * Notice: The portion of the term of this patent 4,900,552 2/1990 Sanvordeker .... ... 424/422 subsequent to Aug. 10, 2010 has been 4,900,554 2/1990 Yanagibashi. ... 424/448 disclaimed. 4,937,078 6/1990 Mezei........... ... 424/450 Appl. No.: 112,330 4,940,587 7/1990 Jenkins ..... ... 424/480 21 4,981,875 l/1991 Leusner ... ... 514/774 22 Filed: Aug. 27, 1993 5,023,082 6/1991 Friedman . ... 424/426 5,234,957 8/1993 Mantelle ........................... 514/772.6 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation-in-part of PCT/US92/01730, Feb. 27, 0002425 6/1979 European Pat. Off. 1992, which is a continuation-in-part of Ser. No. 0139127 5/1985 European Pat. Off. 813,196, Dec. 23, 1991, Pat. No. 5,234,957, which is a 0159168 10/1985 European Pat.
    [Show full text]